• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常用骨肿瘤研究细胞系的分子特征:跨欧 EuroBoNet 研究。

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.

机构信息

Institute of Pathology, University Medical Center Duesseldorf, Duesseldorf, Germany.

出版信息

Genes Chromosomes Cancer. 2010 Jan;49(1):40-51. doi: 10.1002/gcc.20717.

DOI:10.1002/gcc.20717
PMID:19787792
Abstract

Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences among subclones or contamination with mycoplasm or other immortal mammalian cells. To overcome these limitations, we decided within the EuroBoNeT consortium to characterize a common set of cell lines including osteosarcomas (OS), Ewing sarcomas (ES), and chondrosarcomas (CS). DNA fingerprinting was used to guarantee the identity of all of the cell lines and to distinguish subclones of osteosarcoma cell line HOS. Screening for homozygous loss of 38 tumor suppressor genes by MLPA revealed deletion of CDKN2A as the most common event (15/36), strictly associated with absence of the CDKN2A (p16) protein. Ten cell lines showed missense mutations of the TP53 gene while another set of nine cell lines showed mutations resulting in truncation of the TP53 protein. Cells harboring missense mutations expressed high levels of nuclear TP53, while cell lines with nonsense mutations showed weak/absent staining for TP53. TP53(wt) cell lines usually expressed the protein in 2-10% of the cells. However, seven TP53(wt) osteosarcomas were negative for both mRNA and protein expression. Our analyses shed light on the correlation between immunohistochemical and genetic data for CDKN2A and TP53, and confirm the importance of these signaling pathways. The characterization of a substantial number of cell lines represents an important step to supply research groups with proven models for further advanced studies on tumor biology and may help to make results from different laboratories more comparable.

摘要

癌细胞系的使用反复产生了冲突的结果,这些结果是由于亚克隆之间的差异或支原体或其他永生化哺乳动物细胞的污染引起的。为了克服这些限制,我们在 EuroBoNeT 联盟内决定对一组包括骨肉瘤 (OS)、尤文肉瘤 (ES) 和软骨肉瘤 (CS) 的常见细胞系进行特征描述。DNA 指纹分析用于保证所有细胞系的身份,并区分骨肉瘤细胞系 HOS 的亚克隆。通过 MLPA 对 38 个肿瘤抑制基因的纯合缺失进行筛选,发现 CDKN2A 的缺失是最常见的事件 (15/36),与 CDKN2A(p16)蛋白的缺失严格相关。10 个细胞系显示 TP53 基因的错义突变,而另一组 9 个细胞系显示导致 TP53 蛋白截断的突变。携带错义突变的细胞表达高水平的核 TP53,而具有无意义突变的细胞系对 TP53 的染色较弱/缺失。携带错义突变的 TP53(wt)细胞系通常在 2-10%的细胞中表达该蛋白。然而,7 个 TP53(wt)骨肉瘤在 mRNA 和蛋白表达上均为阴性。我们的分析阐明了 CDKN2A 和 TP53 的免疫组织化学和遗传数据之间的相关性,并证实了这些信号通路的重要性。大量细胞系的特征描述是为研究小组提供经过验证的模型以进行肿瘤生物学的进一步深入研究的重要步骤,并且可能有助于使不同实验室的结果更加可比。

相似文献

1
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.常用骨肿瘤研究细胞系的分子特征:跨欧 EuroBoNet 研究。
Genes Chromosomes Cancer. 2010 Jan;49(1):40-51. doi: 10.1002/gcc.20717.
2
TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.TabBO:一种反映去势抵抗性前列腺癌常见分子特征的模型。
Clin Cancer Res. 2000 Mar;6(3):1190-7.
3
Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.CHEK2和TP53突变的独特替代与原发性前列腺肿瘤和癌细胞系有关。
Hum Mutat. 2006 Oct;27(10):1062-3. doi: 10.1002/humu.9457.
4
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.TP53突变的存在与位置决定了膀胱癌中CDKN2A/ARF通路的失活模式。
Cancer Res. 1998 Dec 1;58(23):5348-53.
5
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.对头颈部鳞状细胞癌中CDKN2B(p15INK4b)、CDKN2A(p14ARF、p16INK4a)和MTAP基因的基因结构精细定位缺失。
Arch Otolaryngol Head Neck Surg. 2006 Apr;132(4):409-15. doi: 10.1001/archotol.132.4.409.
6
Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.p53和p16的详细计算研究:利用进化序列分析和疾病相关突变预测等位基因变异的功能后果。
Oncogene. 2003 Feb 27;22(8):1150-63. doi: 10.1038/sj.onc.1206101.
7
Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.在缺乏p53突变的晚期卵巢癌中,p16肿瘤抑制基因表达缺失更为常见。
Gynecol Oncol. 2001 Dec;83(3):491-500. doi: 10.1006/gyno.2001.6464.
8
Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.p16/MTS1、细胞周期蛋白D1和RB在原发性口腔癌及口腔癌细胞系中的作用
Br J Cancer. 1999 Apr;80(1-2):79-86. doi: 10.1038/sj.bjc.6690505.
9
CDKN2A/p16 is inactivated in most melanoma cell lines.CDKN2A/p16在大多数黑色素瘤细胞系中失活。
Cancer Res. 1997 Nov 1;57(21):4868-75.
10
Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.存档人类实体瘤中细胞周期蛋白依赖性激酶抑制剂2/多重肿瘤抑制基因1(CDKN2/MTS1)产物p16INK4A的免疫组织化学检测:与视网膜母细胞瘤蛋白表达的相关性
Cancer Res. 1995 Dec 15;55(24):6006-11.

引用本文的文献

1
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma.对一批患者来源的异种移植瘤和细胞系进行基因组分析后发现,伊沙匹隆是一种对化疗耐药性骨肉瘤有效的药物。
J Exp Clin Cancer Res. 2025 Jul 8;44(1):195. doi: 10.1186/s13046-025-03440-5.
2
Repurposing riluzole as an anti-osteosarcoma agent.将利鲁唑重新用作抗骨肉瘤药物。
Front Oncol. 2025 May 5;15:1508819. doi: 10.3389/fonc.2025.1508819. eCollection 2025.
3
Endothelial remodeling in osteosarcomas: insights from patient samples and in vitro studies.
骨肉瘤中的内皮重塑:来自患者样本和体外研究的见解
Am J Cancer Res. 2025 Apr 15;15(4):1629-1646. doi: 10.62347/KYFO6159. eCollection 2025.
4
Tumor Growth, Proliferation and Diffusion in Osteosarcoma.骨肉瘤中的肿瘤生长、增殖与扩散
Acta Biotheor. 2025 Mar 18;73(1):4. doi: 10.1007/s10441-025-09494-4.
5
C-terminal binding protein-2 triggers CYR61-induced metastatic dissemination of osteosarcoma in a non-hypoxic microenvironment.C末端结合蛋白2在非缺氧微环境中触发CYR61诱导的骨肉瘤转移扩散。
J Exp Clin Cancer Res. 2025 Mar 5;44(1):83. doi: 10.1186/s13046-025-03350-6.
6
Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches.软骨肉瘤:新的分子见解、床旁前临床建模面临的挑战及治疗方法
Int J Mol Sci. 2025 Feb 12;26(4):1542. doi: 10.3390/ijms26041542.
7
Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells.联合抑制核糖核苷酸还原酶和WEE1在尤因肉瘤细胞中诱导协同抗癌活性。
BMC Cancer. 2025 Feb 17;25(1):277. doi: 10.1186/s12885-025-13691-2.
8
Nucleo-cytoplasmic environment modulates spatiotemporal p53 phase separation.核质环境调节p53的时空相分离。
Sci Adv. 2024 Dec 13;10(50):eads0427. doi: 10.1126/sciadv.ads0427. Epub 2024 Dec 11.
9
Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis.抑制线粒体 OMA1 可改善骨肉瘤的肿瘤发生。
Cell Death Dis. 2024 Nov 1;15(11):786. doi: 10.1038/s41419-024-07127-1.
10
Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management.在临床管理中快速建立患者来源的原发性骨肉瘤细胞系的可行性及障碍
iScience. 2024 Jun 19;27(9):110251. doi: 10.1016/j.isci.2024.110251. eCollection 2024 Sep 20.